Genspera Inc (GNSZ) 0.1300 $GNSZ
GenSpera Announces Name Change to Inspyr Therapeutics
BusinessWire - Mon Aug 01, 3:05PM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announces that it will change its corporate name to Inspyr Therapeutics, Inc. and will begin trading on OTC/QB under the ticker symbol NSPX effective August 2, 2016. The Company will also unveil a new corporate website at www.inspyrtx.com.
GenSpera Announces Management Changes
BusinessWire - Tue Mar 22, 4:36PM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that Craig A. Dionne, Ph.D., has resigned as GenSpera's Chairman of the Board and as a Director, and has submitted a notice of termination as GenSpera's CEO and CFO, all effective immediately. Peter E. Grebow Ph.D., a GenSpera Director, has been appointed Interim Chairman. Russell Richerson Ph.D., GenSpera's Chief Operating Officer and Secretary, has been named Interim Principal Executive Officer and Principal Accounting Officer.
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 13.70 (+0.16), EBS: 28.01 (+0.09), ARWR: 7.50 (+0.44), AMBX: (), PFE: 34.98 (-0.21), ADMP: 2.65 (-0.01), AMGN: 173.62 (-1.13), LLY: 79.06 (-0.72), BIND: 0.78 (-0.09), GSK: 44.16 (-0.33), BMY: 59.29 (+0.61), MDVN: 67.16 (-0.03), PGNX: 6.82 (-0.06), GTXI: 0.57 (-0.05), AZN: 33.56 (-0.01), NLNK: 10.06 (-0.19), ABBV: 67.10 (+0.33)
GenSpera Inc. - "An Evening At The Hudson Union Society"
ACCESSWIRE - Wed Dec 09, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / December 9, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Provides Update on Clinical Development Programs
BusinessWire - Fri Nov 13, 6:00AM CST
GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, is providing an update on its clinical development programs and corporate developments.
World-Renowned Neuro-Oncologist Santosh Kesari, MD, PhD Joins GenSpera's Scientific Advisory Board
BusinessWire - Thu Oct 29, 7:00AM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a San Antonio-based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announces that Santosh Kesari, MD, PhD, a board-certified neurologist and neuro-oncologist and a recognized leader in these fields, has joined the company's Scientific Advisory Board.
GenSpera to Present at the BIO Investor Forum
BusinessWire - Wed Oct 14, 6:00AM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage oncology drug discovery company developing a naturally occurring toxin in a targeted delivery system for solid tumors, announces that President and CEO Craig Dionne, Ph.D., is scheduled to present a corporate overview at the 14th Annual BIO Investor Forum on October 21, 2015 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time). The conference is being held at Parc 55 San Francisco hotel in San Francisco.
GenSpera Inc. - "'Precision Medicine' and Biomarkers"
ACCESSWIRE - Fri Sep 18, 10:16AM CDT
NEW YORK, NY / ACCESWIRE / September 18, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Inc. - "Winning the Name Game"
ACCESSWIRE - Thu Sep 10, 7:19AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors
Marketwired - Wed Sep 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that interim data from its Phase II study of mipsagargin (G-202) in adult patients with recurrent or progressive glioblastoma has demonstrated impressive activity in patients to date. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA.
GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Mon Aug 24, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at Rodman & Renshaw's 17th Annual Global Investment Conference on Wednesday, September 9, 2015 from 10:50 to 11:15 AM in Library (2nd floor), St. Regis Hotel, New York City.
GenSpera Provides 2nd Quarter Corporate Update
Marketwired - Mon Aug 10, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) on August 6, 2015, the company reported its financial results for the three and six months ended June 31, 2015, and has provided the following corporate update to its shareholders in order to highlight the Company's extensive organizational advances and clinical progress during the second quarter of 2015. GenSpera continues to unlock conventional thinking to conceive, design, and develop novel cancer therapies. GenSpera's unique technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides targeted release of drug candidates within tumors.
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 1.15 (-0.05), AMBX: (), CLDX: 3.95 (-0.21), AMGN: 173.62 (-1.13), LLY: 79.06 (-0.72), AMPE: 0.87 (-0.03), GSK: 44.16 (-0.33), BMY: 59.29 (+0.61), CLBS: 5.45 (-0.02), ARGS: 4.25 (+0.07), NK: 7.16 (+0.08), CALA: 3.31 (unch), EXEL: 11.00 (+0.03), XLRN: 29.85 (-0.15)
GenSpera Inc. - "Why Partner: The Partnering Process - Part Two"
ACCESSWIRE - Thu Jul 30, 7:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 30, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Inc. - "Why Partner - Part One"
ACCESSWIRE - Wed Jul 29, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 29, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
U.S. Court of Appeals Enters Judgment in Favor of GenSpera
Marketwired - Mon Jul 20, 7:01AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today the U.S. Court of Appeals for the Federal Circuit found in favor of GenSpera.
Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)
Marketwired - Mon Jul 13, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton Biotech, the pioneer in Plant Cell Fermentation (PCF(R)), has had its international patent application WO 2015/0892978 A1 "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE," published by the World Intellectual Property Organization (WIPO).
GenSpera Announces Private Placement of $2.5 Million
Marketwired - Mon Jul 06, 8:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of shares of common stock and warrants to purchase shares of common stock for gross proceeds of $2.5 million.
GenSpera Inc. - "Pricing vs Value of Cancer Drugs"
ACCESSWIRE - Wed Jul 01, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
U.S. Food and Drug Administration's Office of Orphan Products Development Issues Grant Supporting GenSperas Glioblastoma Study
Marketwired - Wed Jun 17, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Santosh Kesari, MD, PhD, Principal Investigator of GenSpera's glioblastoma clinical trial, received an RO-1 grant from the Food and Drug Administration for ongoing mipsagargin clinical trial studies in humans. The clinical trial is being conducted at UC San Diego Moores Cancer Center in La Jolla, CA.
GenSpera Announces Name Change to Inspyr Therapeutics
BusinessWire - Mon Aug 01, 3:05PM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announces that it will change its corporate name to Inspyr Therapeutics, Inc. and will begin trading on OTC/QB under the ticker symbol NSPX effective August 2, 2016. The Company will also unveil a new corporate website at www.inspyrtx.com.
GenSpera Announces Management Changes
BusinessWire - Tue Mar 22, 4:36PM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that Craig A. Dionne, Ph.D., has resigned as GenSpera's Chairman of the Board and as a Director, and has submitted a notice of termination as GenSpera's CEO and CFO, all effective immediately. Peter E. Grebow Ph.D., a GenSpera Director, has been appointed Interim Chairman. Russell Richerson Ph.D., GenSpera's Chief Operating Officer and Secretary, has been named Interim Principal Executive Officer and Principal Accounting Officer.
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 13.70 (+0.16), EBS: 28.01 (+0.09), ARWR: 7.50 (+0.44), AMBX: (), PFE: 34.98 (-0.21), ADMP: 2.65 (-0.01), AMGN: 173.62 (-1.13), LLY: 79.06 (-0.72), BIND: 0.78 (-0.09), GSK: 44.16 (-0.33), BMY: 59.29 (+0.61), MDVN: 67.16 (-0.03), PGNX: 6.82 (-0.06), GTXI: 0.57 (-0.05), AZN: 33.56 (-0.01), NLNK: 10.06 (-0.19), ABBV: 67.10 (+0.33)
GenSpera Inc. - "An Evening At The Hudson Union Society"
ACCESSWIRE - Wed Dec 09, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / December 9, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Provides Update on Clinical Development Programs
BusinessWire - Fri Nov 13, 6:00AM CST
GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, is providing an update on its clinical development programs and corporate developments.
World-Renowned Neuro-Oncologist Santosh Kesari, MD, PhD Joins GenSpera's Scientific Advisory Board
BusinessWire - Thu Oct 29, 7:00AM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a San Antonio-based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announces that Santosh Kesari, MD, PhD, a board-certified neurologist and neuro-oncologist and a recognized leader in these fields, has joined the company's Scientific Advisory Board.
GenSpera to Present at the BIO Investor Forum
BusinessWire - Wed Oct 14, 6:00AM CDT
GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage oncology drug discovery company developing a naturally occurring toxin in a targeted delivery system for solid tumors, announces that President and CEO Craig Dionne, Ph.D., is scheduled to present a corporate overview at the 14th Annual BIO Investor Forum on October 21, 2015 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time). The conference is being held at Parc 55 San Francisco hotel in San Francisco.
GenSpera Inc. - "'Precision Medicine' and Biomarkers"
ACCESSWIRE - Fri Sep 18, 10:16AM CDT
NEW YORK, NY / ACCESWIRE / September 18, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Inc. - "Winning the Name Game"
ACCESSWIRE - Thu Sep 10, 7:19AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors
Marketwired - Wed Sep 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that interim data from its Phase II study of mipsagargin (G-202) in adult patients with recurrent or progressive glioblastoma has demonstrated impressive activity in patients to date. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA.
GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Mon Aug 24, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at Rodman & Renshaw's 17th Annual Global Investment Conference on Wednesday, September 9, 2015 from 10:50 to 11:15 AM in Library (2nd floor), St. Regis Hotel, New York City.
GenSpera Provides 2nd Quarter Corporate Update
Marketwired - Mon Aug 10, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) on August 6, 2015, the company reported its financial results for the three and six months ended June 31, 2015, and has provided the following corporate update to its shareholders in order to highlight the Company's extensive organizational advances and clinical progress during the second quarter of 2015. GenSpera continues to unlock conventional thinking to conceive, design, and develop novel cancer therapies. GenSpera's unique technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides targeted release of drug candidates within tumors.
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 1.15 (-0.05), AMBX: (), CLDX: 3.95 (-0.21), AMGN: 173.62 (-1.13), LLY: 79.06 (-0.72), AMPE: 0.87 (-0.03), GSK: 44.16 (-0.33), BMY: 59.29 (+0.61), CLBS: 5.45 (-0.02), ARGS: 4.25 (+0.07), NK: 7.16 (+0.08), CALA: 3.31 (unch), EXEL: 11.00 (+0.03), XLRN: 29.85 (-0.15)
GenSpera Inc. - "Why Partner: The Partnering Process - Part Two"
ACCESSWIRE - Thu Jul 30, 7:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 30, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Inc. - "Why Partner - Part One"
ACCESSWIRE - Wed Jul 29, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 29, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
U.S. Court of Appeals Enters Judgment in Favor of GenSpera
Marketwired - Mon Jul 20, 7:01AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today the U.S. Court of Appeals for the Federal Circuit found in favor of GenSpera.
Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)
Marketwired - Mon Jul 13, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton Biotech, the pioneer in Plant Cell Fermentation (PCF(R)), has had its international patent application WO 2015/0892978 A1 "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE," published by the World Intellectual Property Organization (WIPO).
GenSpera Announces Private Placement of $2.5 Million
Marketwired - Mon Jul 06, 8:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of shares of common stock and warrants to purchase shares of common stock for gross proceeds of $2.5 million.
GenSpera Inc. - "Pricing vs Value of Cancer Drugs"
ACCESSWIRE - Wed Jul 01, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
U.S. Food and Drug Administration's Office of Orphan Products Development Issues Grant Supporting GenSperas Glioblastoma Study
Marketwired - Wed Jun 17, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Santosh Kesari, MD, PhD, Principal Investigator of GenSpera's glioblastoma clinical trial, received an RO-1 grant from the Food and Drug Administration for ongoing mipsagargin clinical trial studies in humans. The clinical trial is being conducted at UC San Diego Moores Cancer Center in La Jolla, CA.
